Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.65M | 4.17M | 7.25M | 12.09M | -88.82M |
| Total Depreciation and Amortization | 2.30M | 2.09M | 1.68M | 1.56M | 1.40M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.28M | 6.28M | 5.85M | 5.57M | 98.22M |
| Change in Net Operating Assets | -12.35M | -11.61M | -21.44M | -22.86M | -8.31M |
| Cash from Operations | 3.88M | 927.00K | -6.65M | -3.64M | 2.48M |
| Capital Expenditure | -981.00K | -1.01M | -2.21M | -2.32M | -4.70M |
| Sale of Property, Plant, and Equipment | 157.00K | 152.00K | 352.00K | 401.00K | 430.00K |
| Cash Acquisitions | -- | -- | -- | -- | 5.46M |
| Divestitures | -- | -- | -- | -- | -566.00K |
| Other Investing Activities | -3.50M | -4.61M | -8.84M | -17.97M | -17.16M |
| Cash from Investing | -4.33M | -5.47M | -10.70M | -19.88M | -16.54M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.88M | 27.20M | 3.45M | 2.64M | 1.31M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | 2.50M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.85M | -2.22M | -657.00K | -536.00K | -169.00K |
| Cash from Financing | 25.02M | 24.98M | 2.79M | 2.10M | 3.64M |
| Foreign Exchange rate Adjustments | -39.00K | -50.00K | -177.00K | -273.00K | 213.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.54M | 20.39M | -14.74M | -21.70M | -10.21M |